靶向治疗复发后的再次活检。表皮生长因子突变后出现的T790M，基于病例系列探讨部位及原因。

Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series.

作者信息

Zarogoulidis Paul, Rapti Aggeliki, Sardeli Chrysanthi, Chinelis Panagiotis, Athanasiadou Anastasia, Paraskevaidou Katerina, Kallianos Anastasios, Veletza Lemonia, Trakada Georgia, Hohenforst-Schmidt Wolfgang, Huang Haidong

机构信息

Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Second Pulmonary Clinic, 'Sotiria' Chest Diseases Hospital, Athens, Greece.

出版信息

Respir Med Case Rep. 2017 May 30;21:171-175. doi: 10.1016/j.rmcr.2017.05.013. eCollection 2017.

Guidelines for the treatment of non-small cell lung cancer adenocarcinoma positive in epidermal growth factor mutations indicate tyrosine kinase inhibitors. There are currently three tyrosine kinase inhibitors that can be used as first line treatment: gefitinib, erlotinib and afatinib. Regarding erlotinib and afatinib dosage can be modified in the case of severe adverse effects. In the case of disease relapse investigation for T790M mutation has to be made either with re-biopsy or liquid biopsy and osimertinib has to be administered when T790M is diagnosed. Based on a case series we indicate which is the best approach for T790M mutation.